论文部分内容阅读
目的探讨重组人血管内皮抑制素注射液联合顺铂对非小细胞肺癌(NSCLC)患者血管内皮生长因子(VEGF)的影响。方法选取2012年2月—2014年12月遂宁市中心医院收治的NSCLC患者102例,采用随机数字表法分为对照组52例和观察组50例。对照组患者采用顺铂化疗,观察组患者采用重组人血管内皮抑制素注射液联合顺铂化疗,两组患者均治疗2个周期。比较两组患者临床疗效及化疗前后血清VEGF水平。结果观察组患者临床疗效优于对照组(P<0.05)。化疗前两组患者血清VEGF水平比较,差异无统计学意义(P>0.05);化疗后观察组患者血清VEGF水平低于对照组(P<0.05);化疗后两组患者血清VEGF水平均低于治疗前(P<0.05)。两组治疗有效患者血清VEGF下降水平均高于治疗无效患者(P<0.05)。结论重组人血管内皮抑制素注射液联合顺铂治疗NSCLC的临床疗效确切,可有效降低患者血清VEGF水平。
Objective To investigate the effect of recombinant human endostatin injection combined with cisplatin on vascular endothelial growth factor (VEGF) in patients with non-small cell lung cancer (NSCLC). Methods 102 patients with NSCLC admitted from Suining Central Hospital from February 2012 to December 2014 were divided into control group (n = 52) and observation group (n = 50) by random number table. Patients in the control group received chemotherapy with cisplatin, and patients in the observation group received recombinant human endostatin injection combined with cisplatin chemotherapy. Both groups were treated for 2 cycles. The clinical efficacy and serum VEGF levels were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). The level of serum VEGF in the two groups before chemotherapy was significantly lower than that in the control group (P <0.05), but there was no significant difference between the two groups (P> 0.05) Before treatment (P <0.05). Serum VEGF levels in both groups were significantly higher than those in patients with ineffective treatment (P <0.05). Conclusion Recombinant human endostatin injection combined with cisplatin in the treatment of NSCLC has definite curative effect and can effectively reduce the level of serum VEGF in patients.